-INCLUSION CRITERIA

          1. Measurable metastatic or refractory/recurrent human papilloma virus (HPV-16+) cancer
             (determined by in situ hybridization (ISH) or a polymerase chain reaction (PCR)-based
             test).

          2. Patients must be human leukocyte antigens (HLA-A) 02:01-positive.

          3. All patients must have received prior first line standard therapy or declined standard
             therapy, and have been either non-responders (progressive disease) or have recurred.

          4. Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and
             asymptomatic are eligible. Lesions that have been treated with stereotactic
             radiosurgery must be clinically stable for 1 month after treatment for the patient to
             be eligible. Patients with surgically resected brain metastases are eligible.

          5. Greater than or equal to 18 years of age and less than or equal to 70 years of age.

          6. Able to understand and sign the Informed Consent Document.

          7. Willing to sign durable power of attorney

          8. Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1.

          9. Life expectancy of greater than 3 months.

         10. Patients of both genders must be willing to practice birth control from the time of
             enrollment on this study up to 4 months after treatment. Patients must be willing to
             undergo testing for HPV-16 prior to becoming pregnant.

         11. Women of child bearing potential must have a negative pregnancy test because of the
             potentially dangerous effects of the treatment on the fetus.

         12. Serology:

               -  Seronegative for human immunodeficiency virus (HIV) antibody. (The experimental
                  treatment being evaluated in this protocol depends on an intact immune system.
                  Patients who are HIV seropositive can have decreased immune-competence and thus
                  are less responsive to the experimental treatment and more susceptible to its
                  toxicities.)

               -  Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody.
                  If hepatitis C antibody test is positive, then the patient must be tested for the
                  presence of antigen by reverse transcription polymerase chain reaction (RT-PCR)
                  and be hepatitis C virus ribonucleic acid (HCV RNA) negative.

         13. Hematology:

               -  Absolute neutrophil count greater than 1000/mm^3 without the support of
                  filgrastim.

               -  White blood cell (WBC) greater than or equal to 3000/mm^3

               -  Platelet count greater than or equal 100,000/mm^3

               -  Hemoglobin greater than 8.0 g/dL

         14. Chemistry:

               -  Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less than
                  or equal to 2.5 times the upper limit of normal

               -  Serum creatinine less than or equal to 1.6 mg/dL

               -  Total bilirubin less than or equal to to 1.5 mg/dL, except in patients with
                  Gilberts Syndrome who must have a total bilirubin less than 3.0 mg/dL

         15. More than 4 weeks must have elapsed since any prior systemic therapy at the time the
             patient receives the preparative regimen.

        EXCLUSION CRITERIA:

          1. Women of childbearing potential who are pregnant or breastfeeding. There are
             potentially dangerous side effects of the treatment on the fetus or infant.

          2. Active systemic infections (for e.g.: requiring anti-infective treatment), coagulation
             disorders or other active major medical illnesses of the cardiovascular, respiratory
             or immune system, as evidenced by a positive stress thallium or comparable test,
             myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary
             disease.

          3. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency
             Disease).

          4. Concurrent opportunistic infections (The experimental treatment being evaluated in
             this protocol depends on an intact immune system. Patients who have decreased immune
             competence may be less responsive to the experimental treatment and more susceptible
             to its toxicities).

          5. Concurrent systemic steroid therapy.

          6. History of severe immediate hypersensitivity reaction to cyclophosphamide or
             fludarabine.

          7. History of coronary revascularization or ischemic symptoms.

          8. Documented left ventricular ejection fraction (LVEF) of less than or equal to 45%
             tested. The following patients will undergo cardiac evaluations

        a. clinically significant atrial and/or ventricular arrhythmias including but not limited
        to: atrial fibrillation, ventricular tachycardia, second or third degree heart block or

        b. age greater than or equal 60 years old